论文部分内容阅读
目的研究氢氯噻嗪(HCTZ)对不同血管紧张素转化酶(ACE)基因型的原发性高血压患者血浆ACE浓度和血管紧张素Ⅱ(AngⅡ)浓度的影响。方法829例原发性高血压患者同时服用HCTZ12.5mg,qd。6周后资料完整的785例患者按II、ID、DD3种基因型分组,观测不同基因型间血浆ACE浓度、AngⅡ浓度的变化。结果服用HCTZ6周后II、ID、DD型患者血浆ACE浓度较服药前稍增高,但差异无统计学意义;血浆AngⅡ浓度分别升高到(85.56±64.68)、(81.97±57.99)和(80.84±67.96)ng/L,与服药前比较均差异有统计学意义。3组不同基因型患者血浆AngⅡ服药前后组间差异无统计学意义。结论服HCTZ后,3组基因型患者血浆AngⅡ浓度均升高,血浆ACE浓度不是影响血浆AngⅡ浓度的主要因素。
Objective To investigate the effect of hydrochlorothiazide (HCTZ) on plasma ACE concentration and the concentration of angiotensin Ⅱ (Ang Ⅱ) in patients with essential hypertension with different angiotensin converting enzyme (ACE) genotypes. Methods 829 patients with essential hypertension taking HCTZ12.5mg, qd. After 6 weeks, 785 patients with complete data were divided into groups according to II, ID and DD3 genotypes to observe the changes of plasma ACE concentration and Ang Ⅱ concentration among different genotypes. Results After 6 weeks of HCTZ treatment, plasma ACE concentrations in patients with type II, ID and DD were slightly higher than those before medication, but the difference was not statistically significant. Plasma AngⅡ levels were increased to (85.56 ± 64.68), (81.97 ± 57.99) and (80.84 ± 67.96) ng / L, which were significantly different from those before medication. There was no significant difference between the three groups before and after the administration of plasma Ang Ⅱ in different genotypes. Conclusions After taking HCTZ, plasma AngⅡ concentration in three genotypes patients increased, and plasma ACE concentration was not the main factor affecting plasma Ang Ⅱ concentration.